US EditionFDA approval sought of relacorilant for platinum-resistant ovarian...
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA approval sought of relacorilant for platinum-resistant ovarian...
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent nab-paclitaxel, for treating platinum-resistant ovarian cancer. The application is supported by positive data from the pivotal Phase 3 ROSELLA clinical trial (NCT05257408) and other Phase 2 studies, where relacorilant on top of nab-paclitaxel led to slower disease progression and prolo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
